title: Phase I-II trials of poly(ICLC) in malignant brain tumor patients.
abstract: Poly(ICLC) preparation, containing poly-L-lysine and poly(I) . poly(C) at a weight ratio of 1:2, was given intravenously at a dose of 0.05 to 0.2 mg/kg to 7 patients with malignant brain tumor. Poly(ICLC) induced significant serum interferon (more than 100 reference units/ml) in all patients. The highest interferon titer induced was 875 reference units/ml. Severe side effect was not observed except fever. Hypotension, leukopenia and elevation of liver enzyme levels were observed as side effects in a few cases.
mesh_terms: D000328:Adult; D001932:Brain Neoplasms / Q000188:drug therapy*; D002266:Carboxymethylcellulose Sodium / Q000009:adverse effects / Q000627:therapeutic use* / Q000031:analogs & derivatives; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007022:Hypotension / Q000139:chemically induced; D007369:Interferon Inducers / Q000627:therapeutic use*; D007372:Interferons / Q000097:blood; D007970:Leukopenia / Q000139:chemically induced; D008099:Liver / Q000201:enzymology; D008297:Male; D008747:Methylcellulose / Q000031:analogs & derivatives*; D008875:Middle Aged; D008970:Molecular Weight; D010455:Peptides / Q000627:therapeutic use*; D011070:Poly I-C / Q000009:adverse effects / Q000627:therapeutic use*; D011107:Polylysine / Q000009:adverse effects / Q000627:therapeutic use* / Q000031:analogs & derivatives
chemical_list: D007369:Interferon Inducers; D010455:Peptides; D011107:Polylysine; C019531:poly ICLC; D008747:Methylcellulose; D007372:Interferons; D002266:Carboxymethylcellulose Sodium; D011070:Poly I-C